Australia markets closed

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.3450+0.0350 (+1.52%)
At close: 03:59PM EST
2.2000 -0.14 (-6.18%)
After hours: 04:15PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.3100
Open2.2500
Bid2.2000 x 3200
Ask2.3800 x 1200
Day's range2.1917 - 2.3800
52-week range2.0800 - 12.7100
Volume27,420
Avg. volume38,300
Market cap87.46M
Beta (5Y monthly)N/A
PE ratio (TTM)7.82
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

    OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infec

  • GlobeNewswire

    Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

    OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “This has been a very exciting qua

  • GlobeNewswire

    Vaccitech to Present at Upcoming November Investors Conferences

    OXFORD, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Gemma Brown will be presenting at the following investment conferences in November. Event:Jefferi